Revance to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021
July 29 2021 - 8:00AM
Business Wire
Conference Call Scheduled for Thursday, August
5, 2021, at 4:30 p.m. ET.
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology
company focused on innovative aesthetic and therapeutic offerings,
today announced that the company will release second quarter 2021
financial results on Thursday, August 5, 2021, after the close of
market. Revance will host a corresponding conference call and a
live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to
discuss the results and provide a business and pipeline update.
Individuals interested in listening to the conference call may
do so by dialing (855) 453-3827 for domestic callers, or (484)
756-4301 for international callers and reference conference ID:
9755488; or from the webcast link in the investor relations section
of the company's website at: www.revance.com.
A replay of the call will be available beginning August 5, 2021,
at 4:30 p.m. PT / 7:30 p.m. ET to August 6, 2021, at 4:30 p.m. PT /
7:30 p.m. ET. To access the replay, dial (855) 859-2056 or (404)
537-3406 and reference conference ID: 9755488. The webcast will be
available in the investor relations section on the company's
website for 90 days following the completion of the call.
About Revance Therapeutics, Inc.
Revance Therapeutics, Inc. is a biotechnology company focused on
innovative aesthetic and therapeutic offerings, including its
next-generation neuromodulator product, DaxibotulinumtoxinA for
Injection. DaxibotulinumtoxinA for Injection combines a proprietary
stabilizing peptide excipient with a highly purified botulinum
toxin that does not contain human or animal-based components.
Revance has successfully completed a Phase 3 program for
DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is
pursuing U.S. regulatory approval. Revance is also evaluating
DaxibotulinumtoxinA for Injection in the full upper face, including
glabellar lines, forehead lines and crow's feet, as well as in two
therapeutic indications - cervical dystonia and adult upper limb
spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance
owns a unique portfolio of premium products and services for U.S.
aesthetics practices, including the exclusive U.S. distribution
rights to the RHA® Collection of dermal fillers, the first and only
range of FDA-approved fillers for correction of dynamic facial
wrinkles and folds, and the HintMD fintech platform, which includes
integrated smart payment, subscription and loyalty digital
services. Revance has also partnered with Viatris (formerly Mylan
N.V.) to develop a biosimilar to BOTOX®, which would compete in the
existing short-acting neuromodulator marketplace. Revance is
dedicated to making a difference by transforming patient
experiences. For more information or to join our team visit us at
www.revance.com.
“Revance Therapeutics” and the Revance logo are registered
trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid®
and RHA® are trademarks of TEOXANE SA. BOTOX® is a registered
trademark of Allergan, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210729005047/en/
Investors: Revance Therapeutics, Inc.: Jessica Serra,
626-589-1007 jessica.serra@revance.com or Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620 laurence@gilmartinir.com
Media: Revance Therapeutics, Inc.: Sara Fahy,
949-887-4476 sfahy@revance.com or General Media: Goodfuse: Jenifer
Slaw, 347-971-0906 Jenifer.slaw@goodfuse.com or Trade Media: Nadine
Tosk, 504-453-8344 nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Sep 2023 to Sep 2024